EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, 3D Medicines's enterprise value is HK$1,050.5 Mil.
3D Medicines's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$694.5 Mil. Therefore, 3D Medicines's EV-to-Revenue for today is 1.51.
The historical rank and industry rank for 3D Medicines's EV-to-Revenue or its related term are showing as below:
HKSE:01244'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.91 Med: 1.02 Max: 133.97
Current: 1.51
During the past 4 years, the highest EV-to-Revenue of 3D Medicines was 133.97. The lowest was -0.91. And the median was 1.02.
HKSE:01244's EV-to-Revenue is ranked better than 85.36% of 1038
companies
in the Biotechnology industry
Industry Median: 7.97
vs HKSE:01244: 1.51
As of today (2024-05-16), 3D Medicines's stock price is HK$7.22.
3D Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$3.05. Therefore, 3D Medicines's PS Ratio for today is 2.37.
3D Medicines EV-to-Revenue Historical Data
The historical data trend for 3D Medicines's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of 3D Medicines's EV-to-Revenue
For the Biotechnology subindustry, 3D Medicines's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Medicines's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Medicines's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where 3D Medicines's EV-to-Revenue falls into.
3D Medicines's current Enterprise Value is HK$1,050.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3D Medicines's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$694.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3D Medicines (HKSE:01244) EV-to-Revenue Explanation
3D Medicines's share price for today is HK$7.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$3.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3D Medicines EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of 3D Medicines's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01244 has been successfully added to your